Gold bars to be exempt from tariffs, White House clarifies
DHAKA - Beximco Pharmaceuticals Limited (AIM:BXP), a prominent manufacturer of generic pharmaceuticals, has announced a delay in the Bangladesh Securities and Exchange Commission’s (BSEC) directive to appoint nine independent non-executive directors to its Board. The High Court hearing on the matter is in progress, with a further session scheduled post the High Court’s planned closures, extending the decision timeline to the end of June.
The BSEC order, initially disclosed on March 21, 2025, is part of the regulatory body’s oversight but has met with procedural delays. Beximco Pharma has stated that it will make further announcements as the situation develops.
This development follows Beximco Pharma’s consistent growth in the pharmaceutical sector, with a portfolio that includes a wide range of generic medicines and active pharmaceutical ingredients. The company, founded in 1976, has expanded its reach to over 50 countries, driven by a workforce of over 6000 employees. Its manufacturing facilities meet global regulatory standards, including those of the USA, Europe, Australia, Canada, and Latin America.
Investors and stakeholders are advised to await further updates, as the outcome of the High Court’s decision could influence the company’s governance structure. Beximco Pharma continues to focus on its mission to provide accessible contemporary medicines globally, while navigating the regulatory landscapes of its operational territories.
The information in this article is based on a press release statement from Beximco Pharmaceuticals Limited.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.